AbbVie Snags FDA Approval for Another Indication. Will It Become Another Blockbuster?

AbbVie Snags FDA Approval for Another Indication. Will It Become Another Blockbuster?

Submitted by admin on February 18, 2022 - 10:30am
Source: 
Motley Fool
News Tags: 
AbbVie
Skyrizi
FDA
psoriatic arthritis
Headline: 
AbbVie Snags FDA Approval for Another Indication. Will It Become Another Blockbuster?
snippet: 
  • Skyrizi has a new addressable market of several hundred thousand patients.
  • It looks like the psoriatic arthritis indication could lead to $1.1 billion in annual sales.
  • AbbVie offers investors an enticing 4% dividend yield and the pipeline to support the dividend in the years ahead.

Do Not Allow Advertisers to Use My Personal information